A Physically Active Status Affects the Circulating Profile of Cancer-Associated miRNAs

Martina Faraldi 1, Laura Gerosa 2,*, Marta Gomarasca 1, Veronica Sansoni 1, Silvia Perego 1, Ewa Ziemann 3, Giuseppe Banfi 1,4 and Giovanni Lombardi 1,3

1 IRCCS Istituto Ortopedico Galeazzi, Laboratory of Experimental Biochemistry & Molecular Biology, 20161 Milano, Italy; martina.faraldi@grupposandonato.it (M.F.); marta.gomarasca@grupposandonato.it (M.G.); veronica.sansoni@grupposandonato.it (V.S.); silvia.perego@grupposandonato.it (S.P.); banfi.giuseppe@unisr.it (G.B.); giovanni.lombardi@grupposandonato.it (G.L.)
2 Gruppo San Donato Foundation, 20122 Milano, Italy
3 Department of Athletics, Strength and Conditioning, Poznań University of Physical Education, 61-871 Poznań, Poland; ziemann@awf.poznan.pl
4 Vita-Salute San Raffaele University, 20132 Milano, Italy
* Correspondence: laura.gerosa@grupposandonato.it; Tel.: +39-0216621406

Abstract: Circulating miRNAs are ideal diagnostics and prognostics biomarkers in cancer since altered levels of specific miRNAs have been associated to development/progression of several cancers. Physical activity is a recognized preventive strategy against several cancers, but it may also modify the baseline levels of cancer-associated miRNAs and, hence, may act as a confounding pre-analytical variable. This study aimed at understanding whether physical activity-dependent changes in cancer-associated circulating miRNAs profile could act as a confounding variable. A panel comprising 179 miRNAs was assayed in plasma from 20 highly trained and 10 sedentary men. RT-qPCR data were analyzed with the 2−ΔΔCT methods and normalized on hsa-miR-320d, as determined by bioinformatics analysis. miRNAs associated with the diagnosis of the most prevalent cancers were considered. Only those miRNAs, relevantly associated with cancers, found ≥2-fold up- or downregulated in highly trained subjects compared to sedentary were disclosed. The results reveal that chronic physical activity determined modifications altering the baseline level of several cancer-associated miRNAs and, hence, their diagnostic and prognostic potential. In conclusion, based on our results, a physically active status emerges as an important pre-analytical variable able to alter the basal level of circulating miRNAs, and these alterations might be considered as potentially misleading the analytical output.

Keywords: circulating miRNAs; cancer biomarkers; physical activity; pre-analytical variables

1. Introduction

MicroRNAs (miRNAs) are small non-coding RNA molecules (18–22 nucleotides in length), actively regulating gene expression [1,2]. Several miRNAs display a certain degree of cell- or tissue-specificity, while others are more broadly expressed [3]. Since released in biological fluids [4], they can be detected and quantified in blood [5]. Although circulating miRNAs levels are very low and, however, much lower than in the tissue/cells source [6], they give particular advantage in the case of tissues hardly subjectable to biopptic procedures (e.g., bone and cartilage) [7,8] and/or to serial monitoring the progress of diseases, such as osteoporosis, fracture risk [9] and tumors [10], as well as the response to physical activity [11,12].

During neoplastic transformation, miRNAs may be aberrantly expressed and miRNA signatures can be associated with specific tumors and, possibly, with a given tumor stage [13]. Altered circulating miRNA profiles have been associated with...
transformation and tumor growth, progression, metastasis and development of drug resistance. Consequently, circulating miRNAs profiling is of great interest in cancer diagnosis and prognosis [14]. Further, circulating miRNAs do not only passively mark a pathological condition, by mirroring the tumor cell content, but they can actively act as paracrine/endocrine mediators that target other tissues to determine, for example, the appropriate microenvironment to host a metastasis [15].

Physical inactivity (PI) is the fourth leading cause of death (5.5% of deaths globally) after hypertension, cigarette smoking and hyperglycemia and just before obesity and overweight [16]. PI independently associates with an increased incidence of cancers in general and specifically for certain tumors (e.g., colorectal, lung, breast, prostate, ovarian, endometrial and esophageal) [17]. The net energy surplus consequent to the sedentary behavior is the underlying cause of the onset of these diseases [18]. The preventive role of exercise training, and particularly of endurance training, is explicated towards a plethora of not completely understood molecular mechanisms [19]. Among these, acute and chronic physical activity (PA) profoundly affects the circulating miRNA profile [20]. The anti-cancer effect of PA may thus be mediated, at least in part, by the alteration of miRNA expression profile: PA may determine a miRNA-based regulatory network that make neoplastic transformation, tumor progression and metastasis less probable [21]. From a diagnostic point of view, however, the physiological differences between sedentary and trained subjects must be considered in a clinical setting since they represent an important source of variability. As such, PA is a pre-analytical variable to be accounted in routine analysis especially when highly sensitive analytes are assayed, such as miRNAs [12,22], but thus far no published papers have investigated how PA affects the circulating miRNA-based diagnosis/prognosis on cancer [21]. Based on this background, this study aimed at determining to what extent a physically active status may act as a pre-analytical variable potentially modifying the diagnostic value of miRNAs in cancer, by comparing the circulating miRNA profile of highly trained subjects and sedentary individuals.

2. Materials and Methods

2.1. Study Population

We recruited 24 volunteer young adult males, preselected based on their physical activity profile. Eligibility criteria were: age range 25–40 years, healthy status, normal body mass index (BMI, 20 ≥ BMI ≥ 25 kg/m²), non-smokers, no recent (in the preceding month) or chronic diseases and/or medications. According to the guidelines from the American College of Sports Medicine (ACSM) [23], participants were grouped as either sedentary or endurance trained. Sedentary individuals (n = 10) perform less than 30 min, 5 days/week (or 150 min/week) of moderate intensity PA. In our setting, endurance trained individuals (n = 14) were non-professional mountain ultra-trail athletes accustomed to vigorous-to-high intensity, high volume, long-lasting endurance PA [23] that were recruited at the end of the 9th week of preparation (tapering week, during which the training volumes are halved [24]) for an ultra-trail mountain marathon. All individuals gave their written consent after being informed about study aim, protocol, procedures, associated benefits and eventual risks, in accordance with the Helsinki Declaration (SportMarker protocol approved by the Comitato Etico Ospedale San Raffaele, Milano, Italy and registered on ClinicalTrials.gov NCT03386981).

2.2. Blood Sampling

All participants were asked to abstain from alcohol, keep a regular diet and avoid any pro-inflammatory activity (shaving, waxing, etc.) in the week before the sampling. Sedentary participants were asked to avoid any PA in the 48 h preceding blood sampling. Trained subjects, instead, were sampled the day before an ultra-trail mountain marathon. According to the most up-to-date pre-analytical warnings, venous blood was collected in K2EDTA tubes (BD Vacutainer®, Becton Dickinson, Franklin Lakes, NJ, USA), and plasma,
obtained following centrifugation at standard conditions of 1300×g for 10 min at room temperature (22 °C), was immediately frozen at −80 °C until assayed.

2.3. miRNA Profiling

miRNA profiling analysis was performed accordingly [20]. Briefly, miRNA-enriched total RNA fraction was isolated from equal aliquot of plasma pooled from each subject using miRCURY™ RNA Isolation Kit (Exiqon A/S, Vedbaek, Denmark); isolation efficiency was checked with synthetic oligonucleotides added at known concentrations (spike-in: UniSp2, UniSp4, UniSp5). Reverse transcription reaction was conducted with miRCURY LNA™ Universal RT miRNA PCR. UniSp6 and cel-39 were used as reaction controls. qPCR was performed on a StepOne Plus (Applied Biosystem, Foster City, CA, USA) using serum/plasma miRCURY LNA™ miRNA focus panel and ExiLENT SYBR Green Master Mix (Exiqon). The qPCR reaction was conducted as follows: polymerase activation for 10 min at 95 °C, amplification (40 cycles: 10 s at 95 °C and 60 s at 60 °C) and melting curves. The analytical output, expressed as quantification cycle (Cq), was analyzed with GenEx software v6 (Exiqon). Three inter-plate (IPC) calibrators, with specific primer pairs and DNA template, were used to adjust Cq values from different plate runs of different experiments. Only miRNAs with a Cq < 37 were further considered in the analysis. The 2−ΔΔCT method was applied to calculate the relative expression of each miRNA, using hsa-miR-320d as normalizers. This miRNA was identified as the most appropriate based on a study of miRNA stability, as previously reported [20]. Hemolysis was checked by hsa-miR-23-a-to-hsa-miR-451 ΔCq difference (positive if >7). Analyses were conducted in triplicate.

2.4. Statistical Analysis

Given their distribution, data from the two cohorts were compared throughout a parametric unpaired t-test with Welch’s correction. Differences were considered significant when \( p < 0.05 \) (Prism® v6.01, GraphPad Software, La Jolla, CA, USA). Only miRNAs with a significant (\( p < 0.05 \)) fold change ≥±2 were considered.

2.5. Article Selection

Published articles on circulating miRNAs associated with cancer were selected on PubMed by searching for “serum miRNAs”, “serum microRNAs”, “plasma miRNAs”, “plasma microRNAs”, “circulating miRNAs”, “circulating microRNAs” with “cancer diagnosis” for five cancers: lung cancer (LC), prostate cancer (PC), colon cancer (CC), liver cancer (HC) and gastroesophageal cancer (GEC) and related subtypes. These cancers were chosen as the five most frequent cancers in males worldwide, according to the “Global Cancer Observatory” (https://gco.iarc.fr/, accessed on 31 December 2020), for which exist evidence, through meta-analysis (published from 2010 to 2020), on association with physical activity (all-cancer risk/mortality [25–29]; LC [30,31]; PC [32]; CC [33–35]; HC [36]; GEC [37–45]). Only studies on human, published from 2010, and demonstrating a clinical relevance for single serum/plasma miRNA or serum/plasma miRNA signatures including at least one of the modulated miRNAs in our trained cohort were considered. The clinical relevance was defined only in the presence of a literature-derived ROC curve analysis resulting in an area under curve (AUC) >0.7, for diagnostic purpose [46]. This search referred to all 179 analyzed miRNAs.

3. Results

3.1. Selection of Cancer-Associated miRNAs

The selection strategy of cancer-associated miRNAs and signatures is summarized in Figure 1.
Figure 1. Description of selection strategy of cancer associated miRNAs and signatures.

The expression profile of a panel of 179 miRNAs (Table S1), the most abundant in circulation, were analyzed in plasma of two cohorts: sedentary and trained cohorts. Thirty-six miRNAs were significantly modulated by PA: 25 miRNAs were ≥2-fold upregulated and 11 were ≥2-fold downregulated (Table 1).

Table 1. Fold-Change analyzed miRNAs significantly ≥2-fold up- or downregulated in trained subjects compared to sedentary subject (p-value < 0.05).

| miRNAs          | Fold-Change | p-Value |
|-----------------|-------------|---------|
| hsa-let-7a-5p   | 0.147       | 0.035   |
| hsa-let-7d-3p   | 0.327       | 0.012   |
| hsa-miR-1       | 32.146      | 0.003   |
| hsa-miR-126-3p  | 0.494       | <0.001  |
| hsa-miR-127-3p  | 33.726      | 0.034   |
| hsa-miR-140-5p  | 0.016       | 0.002   |
| hsa-miR-148b-3p | 32.664      | 0.013   |
| hsa-miR-155-5p  | 32.980      | <0.001  |
| hsa-miR-16-2-3p | 34.059      | 0.028   |
| hsa-miR-181a-5p | 0.015       | <0.001  |
| hsa-miR-186-5p  | 33.453      | 0.028   |
| hsa-miR-199a-5p | 0.008       | 0.022   |
| hsa-miR-20b-5p  | 33.930      | 0.037   |
| hsa-miR-27b-3p  | 0.409       | 0.015   |
| hsa-miR-28-3p   | 33.374      | 0.001   |
| hsa-miR-29a-3p  | 0.015       | <0.001  |
| hsa-miR-29b-3p  | 34.476      | 0.005   |
| hsa-miR-30c-3p  | 32.977      | <0.001  |
| hsa-miR-320a    | 2.378       | 0.018   |
| hsa-miR-320b    | 3.037       | 0.013   |
As shown in Table 2, among the 179 analyzed miRNAs, 133 have been regarded as of diagnostic usefulness for at least one of the five most prevalent cancers: 81 for LC (Table S2), 23 for PC (Table S3), 60 for CC (Table S4), 53 for HC (Table S5) and 73 for GEC (Table S6). Twenty-six miRNAs were significantly ≥2-fold upregulated (15 miRNAs) or ≥2-fold downregulated (11 miRNAs) in trained subjects, compared to sedentary subjects (Table 2).

Table 2. List of all miRNAs, among the 179 assayed miRNAs, with diagnostic potential for at least one of the five most prevalent cancers (lung cancer, prostate cancer, colon cancer, liver cancer and gastro-esophageal cancer). In bold are reported miRNAs significantly (*p*-value < 0.05) ≥2-fold up- or downregulated in trained subjects compared to sedentary subject.

| miRNAs          | Fold-Change | p-Value |
|-----------------|-------------|---------|
| hsa-miR-326     | 34.710      | 0.0027  |
| hsa-miR-335-3p  | 33.395      | 0.027   |
| hsa-miR-376a-3p | 32.728      | 0.015   |
| hsa-miR-378a-3p | 0.031       | 0.014   |
| hsa-miR-382-5p  | 33.174      | 0.001   |
| hsa-miR-409-3p  | 35.541      | <0.001  |
| hsa-miR-421     | 32.351      | 0.007   |
| hsa-miR-423-3p  | 33.454      | 0.028   |
| hsa-miR-424-5p  | 0.031       | 0.015   |
| hsa-miR-495-3p  | 32.963      | 0.019   |
| hsa-miR-502-3p  | 32.979      | 0.019   |
| hsa-miR-505-3p  | 33.851      | 0.036   |
| hsa-miR-574-3p  | 0.256       | 0.002   |
| hsa-miR-629-5p  | 34.614      | 0.001   |
| hsa-miR-874-3p  | 32.953      | 0.019   |
| hsa-miR-93-3p   | 32.869      | 0.017   |
| miRNA          | Mean | SD   |
|---------------|------|------|
| hsa-miR-127-3p | 33.726 | 0.034 |
| hsa-miR-130a-3p | 44.819 | 0.054 |
| hsa-miR-130b-3p | 46.322 | 0.068 |
| hsa-miR-133a-3p | Undetected |  |
| hsa-miR-139-5p | 0.373 | 0.139 |
| hsa-miR-140-5p | 0.016 | 0.002 |
| hsa-miR-141-3p | Undetected |  |
| hsa-miR-142-3p | 0.081 | 0.133 |
| hsa-miR-142-5p | 0.456 | 0.120 |
| hsa-miR-143-3p | Undetected |  |
| hsa-miR-144-3p | 0.077 | 0.352 |
| hsa-miR-144-5p | 47.871 | 0.088 |
| hsa-miR-145-5p | 0.501 | 0.104 |
| hsa-miR-146a-3p | 0.859 | 0.744 |
| hsa-miR-146b-5p | 0.821 | 0.449 |
| hsa-miR-148a-3p | 0.336 | 0.304 |
| hsa-miR-148b-3p | 32.664 | 0.013 |
| miR-150-5p     | 0.998 | 0.995 |
| hsa-miR-151a-3p | 2.649 | 0.423 |
| hsa-miR-151a-5p | 0.355 | 0.233 |
| hsa-miR-152-3p | 0.670 | 0.515 |
| hsa-miR-154-5p | Undetected |  |
| hsa-miR-155-5p | 32.980 | <0.001 |
| hsa-miR-15a-5p | 1.045 | 0.965 |
| hsa-miR-15b-3p | 0.756 | 0.380 |
| hsa-miR-15b-5p | 2.689 | 0.493 |
| hsa-miR-16-2-3p | 34.059 | 0.028 |
| hsa-miR-16-5p  | 1.246 | 0.537 |
| hsa-miR-17-5p  | 4.460 | 0.544 |
| hsa-miR-181a-5p | 0.015 | <0.001 |
| hsa-miR-18a-5p | 0.813 | 0.666 |
| hsa-miR-18b-5p | 0.315 | 0.284 |
| hsa-miR-191-5p | 1.512 | 0.577 |
| hsa-miR-192-5p | 0.623 | 0.262 |
| hsa-miR-193a-5p | Undetected |  |
| hsa-miR-194-5p | 0.934 | 0.771 |
| hsa-miR-195-5p | Undetected |  |
| hsa-miR-197-3p | 1.382 | 0.377 |
| hsa-miR-199a-3p | 0.831 | 0.425 |
| hsa-miR-199a-5p | 0.008 | 0.022 |
| hsa-miR-19a-3p | 0.355 | 0.226 |
| hsa-miR-19b-3p | 0.287 | 0.195 |
| hsa-miR-20a-5p | 0.672 | 0.526 |
| hsa-miR-20b-5p | 33.930 | 0.037 |
| hsa-miR-200a-3p | Undetected |  |
| hsa-miR-200c-3p | 53.405 | 0.247 |
| hsa-miR-205-5p | Undetected |  |
| hsa-miR-21-5p  | 0.969 | 0.896 |
| hsa-miR-210-3p | Undetected |  |
| hsa-miR-215-5p | 0.371 | 0.127 |
| hsa-miR-22-3p  | 0.383 | 0.156 |
| miRNA       | Expression | P-value |
|-------------|------------|---------|
| hsa-miR-22-5p | Undetected |         |
| hsa-miR-221-3p | 0.220      | 0.140   |
| hsa-miR-222-3p | 0.699      | 0.409   |
| hsa-miR-223-3p | 1.005      | 0.990   |
| hsa-miR-223-5p | 0.567      | 0.290   |
| hsa-miR-23a-3p | 0.994      | 0.564   |
| hsa-miR-23b-3p | 1.674      | 0.428   |
| hsa-miR-24-3p | 1.329      | 0.419   |
| hsa-miR-25-3p | 1.311      | 0.443   |
| hsa-miR-26a-5p | 1.436      | 0.717   |
| hsa-miR-27a-3p | 3.069      | 0.276   |
| hsa-miR-27b-3p | 0.409      | 0.015   |
| hsa-miR-29a-3p | 0.015      | <0.001  |
| hsa-miR-29b-3p | 34.476     | <0.001  |
| hsa-miR-29c-3p | 66.131     | 0.185   |
| hsa-miR-30a-5p | Undetected |         |
| hsa-miR-30b-5p | 0.291      | 0.194   |
| hsa-miR-30c-5p | 0.188      | 0.083   |
| hsa-miR-30d-5p | 1.656      | 0.180   |
| hsa-miR-30e-3p | 32.977     | <0.001  |
| hsa-miR-30e-5p | 0.377      | 0.126   |
| hsa-miR-30f-5p | 0.184      | 0.090   |
| hsa-miR-320a | 2.378      | 0.018   |
| hsa-miR-320b | 3.037      | 0.013   |
| hsa-miR-320c | 3.268      | 0.203   |
| hsa-miR-324-3p | 0.561      | 0.086   |
| hsa-miR-326 | 34.710     | 0.003   |
| hsa-miR-328-3p | 1.154      | 0.868   |
| hsa-miR-331-3p | 0.010      | 0.203   |
| hsa-miR-335-3p | 33.395     | 0.027   |
| hsa-miR-335-5p | Undetected |         |
| hsa-miR-339-3p | Undetected |         |
| hsa-miR-339-5p | 0.534      | 0.194   |
| hsa-miR-342-3p | 0.541      | 0.308   |
| hsa-miR-34a-5p | Undetected |         |
| hsa-miR-375 | 0.326      | 0.286   |
| hsa-miR-376c-3p | 44.991     | 0.183   |
| hsa-miR-378a-3p | 0.031      | 0.014   |
| hsa-miR-409-3p | 35.541     | <0.001  |
| hsa-miR-423-3p | 33.454     | 0.028   |
| hsa-miR-423-5p | 1.582      | 0.281   |
| hsa-miR-424-5p | 0.031      | 0.015   |
| hsa-miR-425-3p | 45.356     | 0.077   |
| hsa-miR-425-5p | 1.364      | 0.590   |
| hsa-miR-451a | 0.213      | 0.351   |
| hsa-miR-483-5p | 0.678      | 0.466   |
| hsa-miR-484 | 0.491      | 0.168   |
| hsa-miR-486-5p | 4.640      | 0.173   |
| hsa-miR-497-5p | Undetected |         |
| hsa-miR-574-3p | 0.256      | 0.002   |
| hsa-miR-629-5p | 34.614     | 0.001   |
Several miRNA signatures, associated with the considered cancers, made up by miRNAs included in our panel, have been also considered (Table 3): 30 for LC (Table S2), 1 for PC (Table S3), 17 for CC (Table S4), 6 for HC (Table S5) and 9 for GEC (Table S6). Forty signatures included at least one miRNA that resulted modulated by PA in our experimental setting (Table 3).

Table 3. List of diagnostic signatures for lung (LC), prostate (PC), colon (CC), liver (HC) and gastro-esophageal (GEC) cancers that include miRNAs significantly ≥2-fold up- or downregulated in trained subjects compared to sedentary subject ($p$-value < 0.05).

| Cancer | Signature | miRNA (FC ≥ 2, $p$ < 0.05) | Reference(s) |
|--------|-----------|-----------------------------|--------------|
| LC     | miR-194-5p, miR-451a, miR-486-5p | miR-194-5p, miR-451a, miR-486-5p | [47] |
|        | miR-21, miR-339-5p | miR-21, miR-339-5p | [48] |
|        | let-7b-5p, let-7e-5p, miR-21-5p, miR-24-3p | let-7b-5p, let-7e-5p, miR-21-5p, miR-24-3p | [49] |
|        | miR-15b-3p, miR-16-5p, miR-20a-5p | miR-15b-3p, miR-16-5p, miR-20a-5p | [50] |
|        | miR-146b, miR-205, miR-29c, miR-30b | miR-146b, miR-205, miR-29c, miR-30b | [51] |
|        | miR-145, miR-21 | miR-145, miR-21 | [52] |
|        | miR-19b-3p, miR-21-5p, miR-221-3p, miR-409-3p, miR-425-5p, miR-584-5p | miR-19b-3p, miR-21-5p, miR-221-3p, miR-409-3p, miR-425-5p, miR-584-5p | [53] |
|        | miR-142-5p, miR-146a-5p, miR-223-3p, miR-409-3p | miR-142-5p, miR-146a-5p, miR-223-3p, miR-409-3p | [54] |
|        | miR-106a-5p, miR-181a-5p, miR-21-5p, miR-93-5p | miR-106a-5p, miR-181a-5p, miR-21-5p, miR-93-5p | [55] |
|        | miR-126-3p, miR-145, miR-205-5p, miR-210-3p | miR-126-3p, miR-145, miR-205-5p, miR-210-3p | [56] |
|        | miR-16, miR-205, miR-486 | miR-16, miR-205, miR-486 | [57] |
|        | miR-126, miR-21, miR-210, miR-486-5p | miR-126, miR-21, miR-210, miR-486-5p | [58] |
|        | let-7a, miR-21 | let-7a, miR-21 | [59] |
|        | miR-125a-5p, miR-126, miR-25 | miR-125a-5p, miR-126, miR-25 | [60] |
|        | miR-148a, miR-148b, miR-152, miR-21 | miR-148a, miR-148b, miR-152, miR-21 | [61] |
|        | miR-155, miR-21 | miR-155, miR-21 | [62] |
|        | miR-145, miR-155 | miR-145, miR-155 | [62] |
|        | miR-140-5p, miR-92a | miR-140-5p, miR-92a | [62] |
| PC     | miR-21, and miR-221 | miR-21, and miR-221 | [64] |
miR-23a-3p, miR-27a-3p, miR-142-5p, miR-376c-3p [65]
miR-19a-3p, miR-21-5p, miR-425-5p [66]
miR-21, miR-221, miR-92a [67]
miR-21, miR-92a [68]
miR-130a, miR-27a [69]
miR-18a, miR-21, miR-22, miR-25 [70]
miR-18a, miR-191, miR-221, miR-223, miR-24, miR-92a [71]
miR-223, miR-24, miR-92a [71]
miR-19a, miR-19b [72]
miR-17, miR-21, miR-29a, miR-92 [73]
miR-125b, miR-21, miR-29a [74]
miR-29a, miR-92a [75]
miR-24, miR-320a, miR-423-5p miR-320a [76]
miR-15b, miR-18a, miR-19a, miR-19b, miR-29a, miR-335 miR-29a, miR-335 [77]
miR-155, miR-21, miR-200c, miR-210, miR-29a miR-155, miR-29a [67]
miR-409-3p, miR-7, miR-93 miR-409-3p, miR-93 [78]
miR-101, miR-21, miR-26a [79]
miR-125b, miR-223, miR-26a, miR-27a [80]
miR-10b, miR-106b, miR-181a miR-181a [81]
miR-192-5p, miR-27b-3p miR-27b-3p [82]
miR-122, miR-29b, miR-885-5p miR-29b [83]
miR-106a-5p, miR-17-5p, miR-19b-3p, miR-30a-5p [85]
miR-106a, miR-17 [86]
miR-223, miR-375 [87]
miR-1, miR-20a, miR-27a, miR-34, miR-423-5p [88]
miR-106a, miR-106b, miR-21, miR-93 miR-93 [89]
miR-629, miR-652 miR-629 [90]
miR-16, miR-25, miR-451, miR-486-5p, miR-92a miR-16 [91]
miR-107, miR-144, miR-152, miR-21, miR-342, miR-93 miR-93 [92]
miR-133a-3p, miR-382-5p, miR-451a miR-382-5p [93]

### 3.2. Effects of the Physical Activity Status on the Circulating Levels of miRNAs Associated with Cancers

#### 3.2.1. Lung Cancer

Among the 179 miRNAs, a diagnostic potential in LC and subtypes has been established for 81 miRNAs (Table S2). Of these, 13 resulted modulated by PA in our experimental setting: eight miRNAs were ≥2-fold upregulated (hsa-miR-155-5p, hsa-miR-16-2-3p, hsa-miR-20b-5p, hsa-miR-30e-3p, hsa-miR-320a, hsa-miR-320b, hsa-miR-409-3p and hsa-miR-93-3p) and five were ≥2-fold downregulated (hsa-let-7a-5p, hsa-miR-126-3p, hsa-miR-140-5p, hsa-miR-181a-5p and hsa-miR-199a-5p) (Table 4).

**Table 4.** List of miRNAs significantly ≥2-fold up- or downregulated in trained subjects compared to sedentary subject (p-value < 0.05) and with diagnostic potential for lung (LC), prostate (PC), colon (CC), liver (HC) and gastro-esophageal (GEC) cancers. The modulation of each miRNA, in trained subjects compared to sedentary subjects, is reported as ↑ (upregulated), ↓ (downregulated).

| Cancer | miRNAs | FC ≥ ±2 & p < 0.05 |
|--------|--------|---------------------|
| LC     | hsa-let-7a-5p | ↓ |
|        | hsa-miR-126-3p | ↓ |
|        | hsa-miR-140-5p | ↓ |
|        | hsa-miR-155-5p | ↑ |
|        | hsa-miR-16-2-3p | ↑ |
|        | hsa-miR-181a-5p | ↓ |
|        | hsa-miR-199a-5p | ↓ |
|        | hsa-miR-20b-5p | ↑ |
|        | hsa-miR-30e-3p | ↑ |
|        | hsa-miR-320a | ↑ |
| miRNA          | PC      | CC      | HC      | GEC     |
|---------------|---------|---------|---------|---------|
| hsa-miR-320b  | ↑       | ↓       | ↓       | ↓       |
| hsa-miR-409-3p| ↑       | ↓       | ↓       | ↓       |
| hsa-miR-93-3p | ↑       | ↓       | ↓       | ↓       |
| hsa-let-7a-5p | ↓       | ↑       | ↑       | ↑       |
| hsa-miR-127-3p| ↑       | ↑       | ↑       | ↑       |
| hsa-miR-155-5p| ↑       | ↑       | ↑       | ↑       |
| hsa-miR-181a-5p| ↓     | ↓       | ↓       | ↓       |
| hsa-miR-18b-5p| ↓       | ↓       | ↓       | ↓       |
| hsa-miR-199a-5p| ↓  | ↓       | ↓       | ↓       |
| hsa-miR-29a-3p| ↑       | ↑       | ↑       | ↑       |
| hsa-miR-320a  | ↑       | ↑       | ↑       | ↑       |
| hsa-miR-335a-3p| ↑    | ↑       | ↑       | ↑       |
| hsa-miR-378a-3p| ↓   | ↓       | ↓       | ↓       |
| hsa-miR-424-5p| ↓       | ↓       | ↓       | ↓       |
| hsa-miR-93-3p | ↑       | ↑       | ↑       | ↑       |

hsa-miR-155-5p, hsa-miR-16-2-3p, hsa-miR-20b-5p, hsa-miR-30e-3p, hsa-miR-320a, hsa-miR-320b, hsa-miR-93-3p, hsa-let-7a-5p and hsa-miR-126-3p have been described as discriminating non-small cell lung cancer (NSCLC) patients from healthy individuals. Other miRNAs associated with LC diagnosis (hsa-miR-155-5p in LC; hsa-miR-126-3p, hsa-miR-140-5p and hsa-miR-409-3p in lung adenocarcinoma (LA); and hsa-miR-181a-5p in lung squamous cell carcinoma (LSCC)) were also affected by the training status. Additionally, miRNA included in the analyzed panel were found in 30 miRNA signatures associated with LC diagnosis (Table 3). Twenty-four signatures diagnostic for LC or LC subtypes, included at least one of the 13 miRNAs modulated in the trained cohort: twenty signatures included one of the thirteen miRNAs that resulted modulated in trained subjects, two signatures included two modulated miRNAs and two signatures included three modulated miRNAs.

### 3.2.2. Prostate Cancer

Twenty-three miRNAs, within the analyzed panel, have a diagnostic potential in PC (Table S2). Of these, two miRNAs (hsa-miR-326 and hsa-miR-874a-3p) were found ≥2-fold
significantly upregulated and one (hsa-miR-93-3p) downregulated in trained subjects (Table 4). No miRNA signatures associated with PC diagnosis, including miRNAs modulated in trained individuals, were identified (Table 3).

### 3.2.3. Colon Cancer

Sixty miRNAs, within the analyzed panel, have a diagnostic potential in CC and CRC (Table S4). Of these, 12 were modulated in our experimental setting by PA: hsa-miR-127-3p, hsa-miR-155-5p, hsa-miR-320a, hsa-miR-335a-3p and hsa-miR-93-3p were ≥2-fold significantly upregulated, while hsa-let-7a-5p, hsa-miR-181a-5p, hsa-miR-18b-5p, hsa-miR-199a-5p, hsa-miR-29a-3p, hsa-miR-378a-3p and hsa-miR-424-5p were ≥2-fold significantly downregulated in trained subjects (Table 4). Seventeen miRNA signatures, with diagnostic potential for CC or CRC (Table 3), including several of the 179 analyzed circulating miRNAs, were identified in the literature. Among them, four signatures included one of the eleven miRNAs affected by the trained status and three signatures included two modulated miRNAs (Table 3).

### 3.2.4. Liver Cancer

Fifty-three miRNAs, within the analyzed panel, have a diagnostic potential in HC (Table S5). Of these, six miRNAs were modulated in our experimental setting by physical activity: hsa-miR-29b-3p and hsa-miR-423-3p were ≥2-fold significantly upregulated, while hsa-miR-126-3p, hsa-miR-181a-5p, hsa-miR-29a-3p and hsa-miR-574-3p were ≥2-fold significantly downregulated in trained individuals (Table 4). Six miRNA signatures associated with HC diagnosis include analyzed miRNAs (Table 3): four signatures include one miRNA modulated in trained subjects compared to sedentary subjects.

### 3.2.5. Gastroesophageal Cancer

Seventy-three miRNAs, within the analyzed panel, have a diagnostic potential for GEC (Table S6). Of these, 11 miRNAs were modulated in trained subject compared to sedentary subjects: hsa-miR-127-3p, hsa-miR-16-2-3p, hsa-miR-20b-5p, hsa-miR-629-5p and hsa-miR-93-3p were ≥2-fold significantly upregulated, while hsa-let-7a-5p, hsa-let-7d-3p, hsa-miR-140-5p, hsa-miR-199a-5p, hsa-miR-27b-3p and hsa-miR-378a-3p were ≥2-fold significantly downregulated in trained individuals (Table 4). More specifically, hsa-let-7a-5p, hsa-let-7d-3p, hsa-20b-5p and hsa-miR-93-3p have been described as discriminating between esophageal squamous cell carcinoma (ESCC) patients and healthy individuals, while hsa-miR-140-5p, hsa-miR-16-2-3p, hsa-miR-199a-5p, hsa-miR-27b-3p, hsa-miR-378a-3p, hsa-miR-629-5p and hsa-miR-93-3p are diagnostic for gastric cancer (GC). Among the nine miRNA signatures associated with GEC diagnosis, five signatures include one miRNA that resulted modulated in trained individuals (Table 3).

### 4. Discussion

Several circulating miRNAs, both singularly and grouped in signatures, have been associated with cancer development risk, detection and progression [13]. In parallel, many studies have demonstrated that regular PA reduces the global risk of developing a cancer as well as improves prognosis and reduces the risk of metastasis and side effects of the therapy in subjects treated for primitive tumor [17,94,95]. However, the impact of PA on circulating miRNAs associated with cancer is mostly neglected, as recently reviewed in [21]. Therefore, this study provides first evidence about the alteration in the circulating level of cancer associated miRNAs in response to chronic PA.

The main question this study aimed to address is whether physical active status may represent a modifier of the baseline circulating miRNA profile and, hence, may act as a pre-analytical variable that affect the diagnostic potential of miRNAs associated with cancer. In our study, a panel of 179 circulating miRNAs was analyzed. First, for each miRNA, the association with the five most frequent cancers in males (LC, PC, CC, HC and
GEC) was investigated; only those miRNAs with an established diagnostic potential, defined as the ability to discriminate between cancer patients and healthy subjects and associated to a significant AUC ≥ 0.7, in ROC analysis, was considered. Based on this assumption, we identified 133 miRNAs. Second, the expression profile of the 179-miRNA panel was determined in plasma samples of highly trained subjects and their sedentary counterparts. Only miRNA significantly ≥ 2 fold up- or downregulated in trained subjects, compared to sedentary subjects, were further investigated. As expected, our two cohorts are featured by a different miRNA profile: the expression level of 36 miRNAs (25 upregulated and 11 downregulated) was significantly (p < 0.05) and relevantly (≥ 2 fold) altered in physically active subjects (Table 1). Among these, 26 miRNAs (15 upregulated and 11 downregulated) have been previously associated with at least one of the most frequent cancers in males (see the tables in the Supplementary Materials). Of the 15 upregulated miRNAs, eight have been associated with LC, two with PC and HC and five with CC and GEC. Of the 11 downregulated miRNAs, five have been associated with LC, one with PC, seven with CC, four with HC and six with GEC. These results demonstrate that the adaptation to regular exercise determines a baseline modification of several circulating miRNAs and this fact, if not considered, may limit their clinical applicability, thus confirming previous hypothesis [12]. Similarly, this consideration can be extended to miRNA signatures since 19 miRNAs that resulted significantly modulated by PA are included in diagnostic miRNA signatures from the literature. miRNA signature means a series of miRNAs that have an overall diagnostic potential. A diagnostic miRNA signature does not necessarily include all single miRNA found with diagnostic potential in a specific study; a miRNA signature can also include miRNAs that, singularly, do not have a diagnostic potential. Moreover, a signature can include both miRNAs up- and downregulated in a specific experimental setting. In this study, signatures from the literature that include at least one of the modulated miRNAs in our trained cohort were considered. Based on our literature search, 63 signatures were identified. Of the signatures that include at least one modulated miRNA, in our experimental setting, 24 are associated with LC diagnosis, 0 with PC, 7 with CC, 4 with HC and 5 with GEC. Thereby, the presence of miRNAs affected by physical active status within a diagnostic signature may reduce its clinical reliability. Consequently, the greater is the number of miRNAs modulated by PA within a signature, the lower is the clinical reliability of the signature itself.

From these results, the training status-dependent alterations of the circulating levels of cancer-associated miRNAs in healthy individuals are remarkable. Importantly, 107 miRNAs (of the 133 circulating miRNAs associated with the five cancers) and 23 signatures resulted not affected by regular training, and, given their robustness, the analysis of these miRNAs or signatures might be privileged. Alterations of hematological and biochemical parameters in response to chronic PA are well documented [22], as well as, although to a lesser extent, for miRNAs [12]. Chronic PA alters the level of miRNAs involved in skeletal muscle and bone metabolisms [20], inflammation, immunity and angiogenesis [96], as well as those associated with metabolic syndrome and diabetes [97], cardiovascular disease [98], skeletal muscle and bone diseases [9, 99]. However, the measurement of these indices is challenging. Sample-associated and subject-associated pre-analytical variables must be considered. The former includes patient preparation (timing and posture), sample collection (sample identification and labeling, type of disposables, order of draw, phlebotomy procedure and contamination), transportation (length and environmental conditions), preparation (centrifugation length, speed and temperature and aliquot preparation) and storage (length, temperature and freeze–thaw cycles) [100]. Subject-associated variables, besides the uncontrollable but considerable biological ones (e.g., age, gender, ethnicity, diseases and circannual/seasonal rhythm), include medications, physical activity status (acute and chronic) and menstrual cycle phase, based on which the sampling can be opportunely temporized [101]. As we recently demonstrated for the same set of miRNAs, many of these variables can affect their
determination [102,103], and, according to the present study, the physical activity status must also be considered. Therefore, a strict definition of the pre-analytical variables affecting circulating miRNAs measurement, including PA, is needed to allow a correct interpretation of the final analytical output.

Although based on a solid experimental approach relying on a meticulous control of the pre-analytical phase, and a robust post-analytical data analysis based on a well-defined normalization strategy, this study suffers some limitations that should be taken into consideration. First, the identification of miRNAs and miRNA signatures associated with cancer diagnosis is based on a literature search that, although extensive and systematically conducted, may be not fully exhaustive. In this regard, since the rather not exhaustive information available, it was not possible to select the research articles taking into consideration important variables such as gender, age, medications and comorbidities. Second, different studies may have differently scored a miRNA, and, hence, although the criterion of AUC >0.7 has been established, the actual diagnostic relevance of certain miRNAs may have been under- or overestimated. Third, due to the discrepancies among the studies the limit of having considered healthy subjects, it was not possible to determine whether PA may play a protective role against cancers, other than its only pre-analytical effect. Finally, the sample size could be considered rather small for a case-control study. However, this limitation would be, at least partially, overcome thanks to the very high homogeneity level of the subjects within each of the two cohorts in terms of subject-specific pre-analytical variables (e.g., age range and avoidance from physical activity for the sedentary cohort and physical activity level and training status for trained subjects).

5. Conclusions

Due to the PA contribution to alteration of circulating level of miRNAs, many of which are associated with cancer diagnostic, this study emphasized PA as a pre-analytical variable. The consistent variability of circulating miRNA induced by PA is of great relevance in diagnostics since miRNA variability may reflect the adaptive response of the whole organism to the PA status, rather than the presence of a pathological condition, as cancer. Therefore, further studies are needed to better standardize the PA effects in order to improve the clinical implementation of circulating miRNAs.

Supplementary Materials: The following are available online at www.mdpi.com/2075-4418/11/5/820/s1. Table S1: Fold-change of the 179 miRNAs analyzed in trained subjects compare with sedentary subjects. In bold are reported miRNAs significantly ≥2-fold up- or downregulated in trained subjects compared to sedentary subject (p-value > 0.05). Table S2: List of the miRNAs and miRNA signature associated with diagnosis in lung cancer from the literature. Only miRNAs with significant clinically relevance (AUC ≥ 0.7) and signatures with at least one modulated miRNA from our experimental setting were considered. Table S3: List of the miRNAs and miRNA signature associated with diagnosis in prostate cancer from the literature. Only miRNAs with significant clinically relevance (AUC ≥ 0.7) and signatures with at least one modulated miRNA from our experimental setting were considered. Table S4: List of the miRNAs and miRNA signatures associated with diagnosis in colon cancer from the literature. Only miRNAs with significant clinically relevance (AUC ≥ 0.7) and signatures with at least one modulated miRNA from our experimental setting were considered. Table S5: List of the miRNAs and miRNA signatures associated with diagnosis in liver cancer from the literature. Only miRNAs with significant clinically relevance (AUC ≥ 0.7) and signatures with at least one modulated miRNA from our experimental setting were considered. Table S6: List of the miRNAs and miRNA signature associated with diagnosis in gastro-esophageal cancer from the literature. Only miRNAs with significant clinically relevance (AUC ≥ 0.7) and signatures with at least one modulated miRNA from our experimental setting were considered.

Author Contributions: Conceptualization, M.F., E.Z. and G.L.; methodology, M.F., L.G., M.G. and G.L.; formal analysis, M.F., L.G. and M.G.; investigation, M.F., L.G., M.G., V.S. and S.P.; data curation, M.F., L.G. and M.G.; writing—original draft preparation, M.F., L.G. and M.G.; and
writing—review and editing. E.Z., G.B. and G.L. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by Italian Ministry of Health within the “Ricerca Corrente” funding program.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Ospedale San Raffaele (protocol code SportMarker and 4 February 2016).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Raw data can be found at https://zenodo.org/record/4058363#.YC4d519Kim8, accessed on 30 November 2020.

**Acknowledgments:** The authors thank the participants in the study.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Hammond, S.M. An overview of microRNAs. *Adv. Drug. Deliv. Rev.* **2015**, *87*, 3–14, doi:10.1016/j.addr.2015.05.001.
2. Ha, M.; Kim, V.N. Regulation of microRNA biogenesis. *Nat. Rev. Mol. Cell Biol.* **2014**, *15*, 509–524, doi:10.1038/nrm3838.
3. Ludwig, N.; Leidinger, P.; Becker, K.; Backes, C.; Fehlmann, T.; Pallasch, C.; Rheinheimer, S.; Meder, B.; Stahler, C.; Meese, E.; et al. Distribution of miRNA expression across human tissues. *Nucleic Acids Res.* **2016**, *44*, 3865–3877, doi:10.1093/nar/gkw116.
4. Verderi, C.; Sansoni, V.; Perego, S.; Favero, V.; Vitale, J.; Terrasi, A.; Morotti, A.; Passeri, E.; Lombardi, G.; Corbetta, S. Circulating microRNAs distinguish primary hyperparathyroidism-related from estrogen withdrawal-related osteoporosis in postmenopausal osteoporotic women: A pilot study. *Bone* **2020**, *137*, 115350, doi:10.1016/j.bone.2020.115350.
5. Budd, M.; Banfi, G.; Lombardi, G. The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases. *Biomolecules* **2020**, *10*, 589, doi:10.3390/biom10040589.
6. Jarry, J.; Schadendorf, D.; Greenwood, C.; Spatz, A.; van Kempen, L.C. The validity of circulating microRNAs in oncology: Five years of challenges and contradictions. *Mol. Oncol.* **2014**, *8*, 819–829, doi:10.1016/j.molonc.2014.02.009.
7. Hackl, M.; Heilmeyer, U.; Weilner, S.; Grillari, J. Circulating microRNAs as novel biomarkers for bone diseases—Complex signatures for multifactorial diseases? *Mol. Cell Endocrinol.* **2016**, *432*, 83–95, doi:10.1016/j.mce.2015.10.015.
8. Verderi, C.; Sansoni, V.; Perego, S.; Favero, V.; Vitale, J.; Terrasi, A.; Morotti, A.; Passeri, E.; Lombardi, G.; Corbetta, S. Circulating fractures-related microRNAs distinguish primary hyperparathyroidism-related from estrogen withdrawal-related osteoporosis in postmenopausal osteoporotic women: A pilot study. *Bone* **2020**, *137*, 115350, doi:10.1016/j.bone.2020.115350.
9. Bottani, M.; Banfi, G.; Lombardi, G. The Clinical Potential of Circulating miRNAs as Biomarkers: Present and Future Applications for Diagnosis and Prognosis of Age-Associated Bone Diseases. *Biomolecules* **2020**, *10*, 589, doi:10.3390/biom10040589.
10. Bottani, M.; Banfi, G.; Lombardi, G. Circulating miRNAs as Diagnostic and Prognostic Biomarkers in Common Solid Tumors: Focus on Lung, Breast, Prostate Cancers, and Osteosarcoma. *J. Clin. Med.* **2019**, *8*, 1661, doi:10.3390/jcm8101661.
11. Bottani, M.; Banfi, G.; Lombardi, G. Perspectives on miRNAs as Epigenetic Markers in Osteoporosis and Bone Fracture Risk: A Step Forward in Personalized Diagnosis. *Front. Genet.* **2019**, *10*, 1044, doi:10.3389/fgene.2019.01044.
12. Lombardi, G.; Rovato, S.; Sansoni, V.; Banfi, G. Circulating miRNA as fine regulators of the physiological responses to physical activity: Pre-analytical warnings for a novel class of biomarkers. *Clin. Biochem.* **2016**, *49*, 1331–1339, doi:10.1016/j.clinbiochem.2016.09.017.
13. Wang, H.; Peng, R.; Wang, J.; Qin, Z.; Xue, L. Circulating microRNAs as potential cancer biomarkers: The advantage and disadvantage. *Clin. Epigenet.* **2018**, *10*, 59, doi:10.1186/s13148-018-0492-1.
14. Zhang, B.; Pan, X.; Cobb, G.P.; Anderson, T.A. microRNAs as oncogenes and tumor suppressors. *Dev. Biol.* **2007**, *302*, 1–12, doi:10.1016/j.ydbio.2006.08.028.
15. Yang, Q.; Diamond, M.P.; Al-Hendy, A. The emerging role of extracellular vesicle-derived miRNAs: Implication in cancer progression and stem cell related diseases. *J. Clin. Epigenet.* **2016**, *2*, 13.
16. Lauby-Secretan, B.; Scoccianti, C.; Loosmi, D.; Grosse, Y.; Bianchini, F.; Straif, K.; International Agency for Research on Cancer Handbook Working, G. Body Fatness and Cancer—Viewpoint of the IARC Working Group. *N. Engl. J. Med.* **2016**, *375*, 794–798, doi:10.1056/NEJMr1606602.
17. Rovato, S.; Sansoni, V.; Ziemann, E.; Lombardi, G. Another Weapon against Cancer and Metastasis: Physical-Activity-Dependent Effects on Adiposity and Adipokines. *Int. J. Mol. Sci.* **2021**, *22*, 5, doi:10.3390/ijms22042005.
18. Khandekar, M.J.; Cohen, P.; Spiegelman, B.M. Molecular mechanisms of cancer development in obesity. *Nat. Rev. Cancer* **2011**, *11*, 886–895, doi:10.1038/nrc3174.
19. Bramble, D.M.; Lieberman, D.E. Endurance running and the evolution of Homo. *Nature* **2004**, *432*, 345–352, doi:10.1038/nature03052.
20. Faraldi, M.; Gomarasca, M.; Sansoni, V.; Perego, S.; Banfi, G.; Lombardi, G. Normalization strategies differently affect circulating miRNA profile associated with the training status. *Sci. Rep.* **2019**, *9*, 1584, doi:10.1038/s41598-019-38505-x.

21. Dufresne, S.; Rebillard, A.; Muti, P.; Friedenreich, C.M.; Brenner, D.R. A Review of Physical Activity and Circulating miRNA Expression: Implications in Cancer Risk and Progression. *Cancer Epidemiol. Biomark. Prev.* **2018**, *27*, 11–24, doi:10.1158/1055-9965.EPI-16-0969.

22. Sanchis-Gomar, F.; Lippi, G. Physical activity—An important preanalytical variable. *Biochem. Med.* **2014**, *24*, 68–79, doi:10.11613/BM.2014.009.

23. Thompson, W.R.; Gordon, N.F.; Pescatello, L.S.; American College of Sports Medicine. *ACSM's Guidelines for Exercise Testing and Prescription*, 8th ed.; Lippincott Williams & Wilkins: Philadelphia, PA, USA, 2010.

24. Muijka, I.; Padilla, S. Scientific bases for precompetition tapering strategies. *Med. Sci. Sports Exerc.* **2003**, *35*, 1182–1187, doi:10.1249/01.MSS.0000074448.73931.11.

25. Pedisic, Z.; Shrestha, N.; Kovalchik, S.; Stamatakis, E.; Liangruenrom, N.; Grigic, J.; Titze, S.; Biddle, S.J.; Bauman, A.E.; Oja, P. Is running associated with a lower risk of all-cause, cardiovascular and cancer mortality, and is the more the better? A systematic review and meta-analysis. *Br. J. Sports Med.* **2020**, *54*, 898–905, doi:10.1136/bjsports-2018-100493.

26. Zhao, R.; Bu, W.; Chen, Y.; Chen, X. The Dose-Response Associations of Sedentary Time with Chronic Diseases and the Risk for All-Cause Mortality Affected by Different Health Status: A Systematic Review and Meta-Analysis. *J. Nutr. Health Aging* **2020**, *24*, 63–70, doi:10.1007/s12603-019-1298-3.

27. Li, Y.; Gu, M.; Jing, F.; Cai, S.; Bao, C.; Wang, J.; Jin, M.; Chen, K. Association between physical activity and all cancer mortality: Dose-response meta-analysis of cohort studies. *Int. J. Cancer* **2016**, *138*, 818–832, doi:10.1002/ijc.29828.

28. Liu, L.; Shi, Y.; Li, T.; Qin, Q.; Yin, J.; Pang, S.; Nie, S.; Wei, S. Leisure time physical activity and cancer risk: Evaluation of the WHO’s recommendation based on 126 high-quality epidemiological studies. *Br. J. Sports Med.* **2016**, *50*, 372–378, doi:10.1136/bjsports-2015-094728.

29. Shi, Y.; Li, T.; Wang, Y.; Zhou, L.; Qin, Q.; Yin, J.; Wei, S.; Liu, L.; Nie, S. Household physical activity and cancer risk: A systematic review and dose-response meta-analysis of epidemiological studies. *Sci. Rep.* **2015**, *5*, 14901, doi:10.1038/srep14901.

30. Brenner, D.R.; Yannitos, D.H.; Farris, M.S.; Johansson, M.; Friedenreich, C.M. Leisure-time physical activity and lung cancer risk: A systematic review and meta-analysis. *Lung Cancer* **2016**, *95*, 17–27, doi:10.1016/j.lungcan.2016.01.021.

31. Zhong, S.; Ma, T.; Chen, L.; Chen, W.; Lv, M.; Zhang, X.; Zhao, J. Physical Activity and Risk of Lung Cancer: A Meta-analysis. *Clin. J. Sport Med.* **2016**, *26*, 173–181, doi:10.1097/JSM.0000000000000219.

32. Benke, I.N.; Leitzmann, M.F.; Behrens, G.; Schmid, D. Physical activity in relation to risk of prostate cancer: A systematic review and meta-analysis. *Ann. Oncol.* **2018**, *29*, 1154–1179, doi:10.1016/annonc/mdy073.

33. Wang, J.; Huang, L.; Gao, Y.; Wang, Y.; Chen, S.; Huang, J.; Zheng, W.; Bao, P.; Gong, Y.; Zhang, Y.; et al. Physically active individuals have a 23% lower risk of all colorectal neoplasia and a 27% lower risk of advanced colorectal neoplasia than their non-active counterparts: Systematic review and meta-analysis of observational studies. *Br. J. Sports Med.* **2020**, *54*, 582–591, doi:10.1136/bjsports-2018-100350.

34. Mahmood, S.; Machnis, R.J.; English, D.R.; Karahalios, A.; Lynch, B.M. Domain-specific physical activity and sedentary behaviour in relation to colon and rectal cancer risk: A systematic review and meta-analysis. *Int. J. Epidemiol.* **2017**, *46*, 1797–1813, doi:10.1093/ije/dyx137.

35. Boyle, T.; Keegel, T.; Bull, F.; Heyworth, J.; Fritschi, L. Physical activity and risks of proximal and distal colon cancers: A systematic review and meta-analysis. *J. Natl. Cancer Inst.* **2012**, *104*, 1548–1561, doi:10.1093/jnci/djs354.

36. Baumeister, S.E.; Leitzmann, M.F.; Linseisen, J.; Schlesinger, S. Physical Activity and the Risk of Liver Cancer: A Systematic Review and Meta-Analysis of Prospective Studies and a Bias Analysis. *J. Natl. Cancer Inst.* **2019**, *111*, 1142–1151, doi:10.1093/jnci/djz111.

37. Poorolajal, J.; Moradi, L.; Mohammadi, Y.; Cheraghi, Z.; Gohari-Ensaif, F. Risk factors for stomach cancer: A systematic review and meta-analysis. *Epidemiol. Health* **2020**, *42*, e2020004, doi:10.4178/epih.e2020004.

38. Lam, S.; Hart, A.R. Does physical activity protect against the development of gastroesophageal reflux disease, Barrett’s esophagus, and esophageal adenocarcinoma? A review of the literature with a meta-analysis. *Dis. Esophagus* **2017**, *30*, 1–10, doi:10.1093/dote/dox099.

39. Castro, C.; Peleiteiro, B.; Lunet, N. Modifiable factors and esophageal cancer: A systematic review of published meta-analyses. *J. Gastroenterol.* **2018**, *53*, 37–51, doi:10.1007/s00535-017-1375-5.

40. Psaltopoulou, T.; Ntanasis-Stathopoulos, I.; Tzanninis, I.G.; Kantzanou, M.; Georgiadou, D.; Sergentanis, T.N. Physical Activity and Gastric Cancer Risk: A Systematic Review and Meta-Analysis. *Clin. J. Sport Med.* **2016**, *26*, 445–464, doi:10.1097/JSM.0000000000000316.

41. Singh, S.; Edakkanambeth Varayil, J.; Devanna, S.; Murad, M.H.; Iyer, P.G. Physical activity is associated with reduced risk of gastric cancer: A systematic review and meta-analysis. *Cancer Prev. Res.* **2014**, *7*, 12–22, doi:10.1158/1940-6207.CAPR-13-0282.

42. Abiaye, A.I.; Odesanya, M.O.; Abiaye, A.I.; Ibrahim, N.A. Physical activity and risk of gastric cancer: A meta-analysis of observational studies. *Br. J. Sports Med.* **2015**, *49*, 224–229, doi:10.1136/bjsports-2013-092778.

43. Chen, Y.; Yu, C.; Li, Y. Physical activity and risks of esophageal and gastric cancers: A meta-analysis. *PLoS ONE* **2014**, *9*, e88082, doi:10.1371/journal.pone.0088082.
44. Behrens, G.; Jochem, C.; Keimling, M.; Ricci, C.; Schmid, D.; Leitzmann, M.F. The association between physical activity and gastroesophageal cancer: Systematic review and meta-analysis. *Eur. J. Epidemiol.* **2014**, *29*, 151–170, doi:10.1007/s10654-014-9895-2.

45. Singh, S.; Devanna, S.; Edakkannambeth Varayil, J.; Murad, M.H.; Iyer, P.G. Physical activity is associated with reduced risk of esophageal cancer, particularly esophageal adenocarcinoma: A systematic review and meta-analysis. *BMC Gastroenterol.* **2014**, *14*, 101, doi:10.1186/1471-230X-14-101.

46. Swets, J.A. Measuring the accuracy of diagnostic systems. *Science* **1988**, *240*, 1285–1293, doi:10.1126/science.3287615.

47. Yao, B.; Qu, S.; Hu, R.; Gao, W.; Jin, S.; Liu, M.; Zhao, Q. A panel of miRNAs derived from plasma extracellular vesicles as novel diagnostic biomarkers of lung adenocarcinoma. *FEBS Open Bio* **2019**, *9*, 2149–2158, doi:10.1002/2211-5463.12753.

48. Sun, Y.; Mei, H.; Xu, C.; Tang, H.; Wei, W. Circulating microRNA-339-5p and -21 in plasma as an early detection predictors of lung adenocarcinoma. *Pathol. Res. Pract.* **2018**, *214*, 119–125, doi:10.1016/j.prp.2017.10.011.

49. Jin, X.; Chen, Y.; Chen, H.; Fei, S.; Chen, D.; Cai, X.; Liu, L.; Lin, B.; Su, H.; Zhao, L.; et al. Evaluation of Tumor-Derived Esosomal miRNA as Potential Diagnostic Biomarkers for Early-Stage Non-Small Cell Lung Cancer Using Next-Generation Sequencing. *Clin. Cancer Res.* **2017**, *23*, 5311–5319, doi:10.1158/1078-0432.CCR-17-0577.

50. Fan, L.; Qi, H.; Teng, J.; Su, B.; Chen, H.; Wang, C.; Xia, Q. Identification of serum miRNAs by nano-quantum dots microarray as diagnostic biomarkers for early detection of non-small lung cancer. *Tumour Biol.* **2016**, *37*, 7777–7784, doi:10.1007/s13277-015-4608-3.

51. Yang, X.; Zhang, Q.; Zhang, M.; Su, W.; Wang, Z.; Li, Y.; Zhang, J.; Beer, D.G.; Yang, S.; Chen, G. Serum microRNA Signature Is Capable of Early Diagnosis for Non-Small Cell Lung Cancer. *Int. J. Biol. Sci.* **2019**, *15*, 1712–1722, doi:10.7150/ijbs.33986.

52. Tang, D.; Shen, Y.; Wang, M.; Yang, R.; Wang, Z.; Sui, A.; Jiao, W.; Wang, Y. Identification of plasma microRNAs as novel noninvasive biomarkers for early detection of lung cancer. *Eur. J. Cancer Prev.* **2013**, *22*, 540–548, doi:10.1097/CEJ.0b013e328320536e.

53. Zhou, X.; Wen, W.; Shan, X.; Zhu, W.; Xu, J.; Guo, R.; Cheng, W.; Wang, F.; Qi, L.W.; Chen, Y.; et al. A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis. *Oncotarget* **2017**, *8*, 6513–6525, doi:10.18632/oncotarget.14311.

54. Wang, J.; Zhang, C.; Peng, X.; Liu, K.; Zhao, L.; Chen, X.; Yu, H.; Lai, Y. A combination of four serum miRNAs for screening of lung adenocarcinoma. *Hum. Cell* **2020**, *33*, 830–838, doi:10.1016/j.humcel.2020.03-0046-6.

55. Shan, X.; Zhang, H.; Zhang, L.; Zhou, X.; Wang, T.; Zhang, J.; Shu, Y.; Zhu, W.; Wen, W.; Liu, P. Identification of four plasma microRNAs as potential biomarkers in the diagnosis of male lung squamous cell carcinoma patients in China. *Cancer Med.* **2018**, *7*, 2370–2381, doi:10.1002/cam4.1490.

56. Li, J.; Fang, H.; Jiang, F.; Ning, Y. External validation of a panel of plasma microRNA biomarkers for lung cancer. *Biomark. Med.* **2019**, *13*, 1557–1564, doi:10.2217/bmm-2019-0213.

57. Sromek, M.; Glogowski, M.; Chechlińska, M.; Kulinczak, M.; Szafron, L.; Zakrzewska, K.; Owczarek, J.; Wisniewski, P.; Włodarczyk, R.; Talarek, L.; et al. Changes in plasma miR-9, miR-16, miR-205 and miR-486 levels after non-small cell lung cancer resection. *Cell Oncol.* **2017**, *40*, 529–536, doi:10.1007/s13402-017-0334-8.

58. Shen, J.; Todd, N.W.; Zhang, H.; Yu, L.; Lingxiao, X.; Mei, Y.; Guarnera, M.; Liao, J.; Chou, A.; Lu, C.L.; et al. Plasma microRNAs as potential biomarkers for non-small-cell lung cancer resection. *Lab. Invest.* **2011**, *91*, 579–587, doi:10.1038/layinvest.2010.194.

59. Wang, L.; Liu, Y.; Du, L.; Li, J.; Jiang, X.; Zheng, G.; Qu, A.; Wang, H.; Wang, L.; Zhang, X.; et al. Identification and validation of reference genes for the detection of serum microRNAs by reverse transcription-quantitative polymerase chain reaction in patients with bladder cancer. *Mol. Med. Rep.* **2015**, *12*, 615–622, doi:10.3892/mmr.2015.3428.

60. Wang, P.; Yang, D.; Zhang, H.; Wei, X.; Ma, T.; Cheng, Z.; Hong, Q.; Hu, J.; Zhuo, H.; Song, Y.; et al. Early Detection of Lung Cancer in Serum by a Panel of MicroRNA Biomarkers. *Clin. Lung Cancer* **2015**, *16*, 313–319.e1, doi:10.1016/j.clc.2014.12.006.

61. Yang, J.S.; Li, B.J.; Lu, H.W.; Chen, Y.; Lu, C.; Zhu, R.X.; Liu, S.H.; Yi, Q.T.; Li, J.; Song, C.H. Serum miR-152, miR-148a, miR-148b, and miR-21 as novel biomarkers in non-small cell lung cancer screening. *Tumour Biol.* **2015**, *36*, 3035–3042, doi:10.1007/s13277-014-2938-1.

62. Zhang, Y.H.; Jin, M.; Li, J.; Kong, X. Identifying circulating miRNA biomarkers for early diagnosis and monitoring of lung cancer. *Biochim. Biophys. Acta Mol. Basis Dis.* **2020**, *1866*, 166847, doi:10.1016/j.bbadis.2020.165847.

63. Chen, H.; Hu, Z.; Wang, W.; Ba, Y.; Ma, L.; Zhang, C.; Wang, C.; Ren, Z.; Zhao, Y.; Wu, S.; et al. Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. *Int. J. Cancer* **2012**, *130*, 1620–1628, doi:10.1002/ijic.26177.

64. Yaman Agaoglu, F.; Kovancilar, M.; Dizdar, Y.; Darendeliler, E.; Holdenrieder, S.; Dalay, N.; Gezer, U. Investigation of miR-21, miR-141, and miR-221 in blood circulation of patients with prostate cancer. *Tumour Biol.* **2011**, *32*, 583–588, doi:10.1007/s13277-011-0154-9.

65. Vychytilova-Faltejskova, P.; Radova, L.; Sachlova, M.; Kosarova, Z.; Slaba, K.; Fabian, P.; Grolich, T.; Prochazka, V.; Kala, Z.; Svoboda, M.; et al. Serum-based microRNA signatures in early diagnosis and prognosis prediction of colon cancer. *Carcinogenesis* **2016**, *37*, 941–950, doi:10.1093/carcin/bgw078.

66. Zhu, M.; Huang, Z.; Zhu, D.; Zhou, X.; Shan, Q.; Li, Q.W.; Wu, L.; Cheng, W.; Zhu, J.; Zhang, L.; et al. A panel of microRNA signature in serum for colorectal cancer diagnosis. *Oncotarget* **2017**, *8*, 17081–17091, doi:10.18632/oncotarget.15059.
Novel Diagnostic and Prognostic Biomarkers of Colorectal Cancer.

Liu, X.; Pan, B.; Sun, L.; Chen, X.; Zeng, K.; Hu, X.; Xu, T.; Xu, M.; Wang, S. Circulating Exosomal miR-27a and miR-130a Act as early detection biomarkers for colorectal cancer. *Cancer Epidemiol. Biomark. Prev.* 2018, 27, 746–754, doi:10.1158/1055-9965.EPI-18-0067.

Wikberg, M.L.; Myte, R.; Palmqvist, R.; van Guelpen, B.; Ljuslin der, I. Plasma miRNA can detect colorectal cancer, but how does it work? *Cancer Med.* 2017, 6, 1697–1705, doi:10.1002/cam4.1398.

Chang, P.Y.; Chen, C.C.; Chang, Y.S.; Tsai, W.S.; You, J.F.; Lin, G.P.; Chen, T.W.; Chen, J.S.; Chan, E.C. MicroRNA-223 and microRNA-92a in stool and plasma samples act as complementary biomarkers to increase colorectal cancer detection. *OncoTarget* 2016, 7, 10663–10679, doi:10.18632/oncotarget.7119.

Giralde, M.D.; Lozano, J.J.; Ramirez, G.; Hijona, E.; Bujanda, L.; Castells, A.; Gironella, M. Circulating microRNAs as biomarkers of colorectal cancer: Results from a genome-wide profiling and validation study. *Clin. Gastroenterol. Hepatol.* 2013, 11, 681–688.e3, doi:10.1016/j.cgh.2012.12.009.

Convy, N.V.; Donev, I.S.; Konsooulou-Kirova, A.A.; Chervenkov, T.G.; Kashlov, J.K.; Ivanov, K.D. Serum expression levels of miR-17, miR-21, and miR-92 as potential biomarkers for recurrence after adjuvant chemotherapy in colon cancer patients. *Biosci. Trends* 2015, 9, 393–401, doi:10.5582/bst.2015.01170.

Yamada, A.; Horimatsu, T.; Okugawa, Y.; Nishida, N.; Honjo, H.; Ida, H.; Kou, T.; Kusaka, T.; Sasaki, Y.; Yagi, M.; et al. Serum miR-21, miR-29a, and miR-125b Are Promising Biomarkers for the Early Detection of Colorectal Neoplasia. *Clin. Cancer Res.* 2015, 21, 4234–4242, doi:10.1158/1078-0432.CCR-14-2793.

Huang, Z.; Huang, D.; Ni, S.; Peng, Z.; Sheng, W.; Du, X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. *Int. J. Cancer* 2010, 127, 118–126, doi:10.1002/ijc.25007.

Fang, Z.; Tang, J.; Bai, Y.; Lin, H.; You, H.; Jin, H.; Lin, L.; You, P.; Li, J.; Dai, Z.; et al. Plasma levels of microRNA-24, microRNA-320a, and microRNA-423-5p are potential biomarkers for colorectal carcinoma. *J. Exp. Clin. Cancer Res.* 2015, 34, 86, doi:10.1186/s13046-015-0198-6.

Herreros-Villanueva, M.; Duran-Sanchez, S.; Martin, A.C.; Perez-Palacios, R.; Vila-Navarro, E.; Marcuello, M.; Diaz-Centeno, M.; Cubiella, J.; Diez, M.S.; Bujanda, L.; et al. Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. *Clin. Transl. Gastroenterol.* 2019, 10, e0003, doi:10.14309/ctg.0000000000000003.

Wang, S.; Xiang, J.; Li, Z.; Lu, S.; Hu, J.; Gao, X.; Yu, L.; Wang, L.; Wang, J.; Wu, Y.; et al. A plasma microRNA panel for early detection of colorectal cancer. *Int. J. Cancer* 2015, 136, 152–161, doi:10.1002/ijc.28136.

Zhuang, C.; Jiang, W.; Huang, D.; Xu, L.; Yang, Q.; Zheng, L.; Wang, X.; Hu, L. Serum miR-21, miR-26a and miR-101 as potential biomarkers of hepatocellular carcinoma. *Clin. Res. Hepatol. Gastroenterol.* 2016, 40, 386–396, doi:10.1016/j.cjgh.2015.11.002.

Zuo, D.; Chen, L.; Liu, X.; Wang, X.; Xi, Q.; Luo, Y.; Zhang, N.; Guo, H. Combination of miR-125b and miR-27a enhances sensitivity and specificity of AFP-based diagnosis of hepatocellular carcinoma. *Tumour Biol.* 2016, 37, 6539–6549, doi:10.1007/s13277-015-4545-1.

Jiang, L.; Cheng, Q.; Zhang, B.H.; Zhang, M.Z. Circulating microRNAs as biomarkers in hepatocellular carcinoma screening: A validation set from China. *Medicine* 2015, 94, e603, doi:10.1097/MD.0000000000000603.

Zhu, H.T.; Liu, R.B.; Liang, Y.Y.; Hasan, A.M.E.; Wang, H.Y.; Shao, Q.; Zhang, Z.C.; Wang, J.; He, C.Y.; Wang, F.; et al. Serum microRNA profiles as diagnostic biomarkers for HBV-positive hepatocellular carcinoma. *Liver Int.* 2017, 37, 888–896, doi:10.1111/liv.13356.

Zekri, A.N.; Youssef, A.S.; El-Desouky, E.D.; Ahmed, O.S.; Lotfy, M.M.; Nassar, A.A.; Bahnassey, A.A. Serum microRNA panels as potential biomarkers for early detection of hepatocellular carcinoma on top of HCV infection. *Tumour Biol.* 2016, 37, 12273–12286, doi:10.1007/s13277-016-5097-8.

Li, L.M.; Hu, Z.B.; Zhou, Z.X.; Chen, X.; Liu, F.Y.; Zhang, J.F.; Shen, H.B.; Zhang, C.Y.; Zen, K. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. *Cancer Res.* 2010, 70, 9798–9807, doi:10.1158/0008-5472.CAN-10-1001.

Wang, N.; Wang, L.; Yang, Y.; Gong, L.; Xiao, B.; Liu, X. A serum exosomal microRNA panel as a potential biomarker test for gastric cancer. *Biochem. Biophys. Res. Commun.* 2017, 493, 1322–1328, doi:10.1016/j.bbrc.2017.10.003.

Zhou, H.; Guo, J.M.; Lou, Y.R.; Zhang, X.J.; Zhong, F.D.; Jiang, Z.; Cheng, J.; Xiao, B.X. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. *J. Mol. Med.* 2010, 88, 709–717, doi:10.1007/s00109-010-0617-2.

Wu, C.; Li, M.; Hu, C.; Duan, H. Clinical significance of serum miR-223, miR-25 and miR-375 in patients with esophageal squamous cell carcinoma. *Mol. Biol. Rep.* 2014, 41, 1257–1266, doi:10.1007/s11033-013-2970-z.

Liu, R.; Zhang, C.; Hu, Z.; Li, G.; Wang, C.; Yang, C.; Huang, D.; Chen, X.; Zhang, H.; Zhuang, R.; et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. *Eur. J. Cancer* 2011, 47, 784–791, doi:10.1016/j.ejca.2010.02.025.

Zhao, G.; Jiang, T.; Liu, Y.; Huai, G.; Lan, C.; Li, G.; Jia, G.; Wang, K.; Yang, M. Droplet digital PCR-based circulating microRNA detection serve as a promising diagnostic method for gastric cancer. *BMC Cancer* 2018, 18, 676, doi:10.1186/s12885-018-4601-5.
90. Shin, V.Y.; Ng, E.K.; Chan, V.W.; Kwong, A.; Chu, K.M. A three-miRNA signature as promising non-invasive diagnostic marker for gastric cancer. *Mol. Cancer* **2015**, *14*, 202, doi:10.1186/s12943-015-0473-3.

91. Zhu, C.; Ren, C.; Han, J.; Ding, Y.; Du, J.; Dai, N.; Dai, J.; Ma, H.; Hu, Z.; Shen, H.; et al. A five-microRNA panel in plasma was identified as potential biomarker for early detection of gastric cancer. *Br. J. Cancer* **2014**, *110*, 2291–2299, doi:10.1038/bjc.2014.119.

92. Sharma, P.; Saraya, A.; Sharma, R. Serum-based six-miRNA signature as a potential marker for EC diagnosis: Comparison with TCGA miRNAseq dataset and identification of miRNA-mRNA target pairs by integrated analysis of TCGA miRNAseq and RNAsseq datasets. *Asia Pac. J. Clin. Oncol.* **2018**, *14*, e289–e301, doi:10.1111/ajco.12847.

93. Bus, P.; Kestens, C.; Ten Kate, F.J.; Peters, W.; Drenth, J.P.; Roodhart, J.M.; Siersema, P.D.; van Baal, J.W. Profiling of circulating microRNAs in patients with Barrett’s esophagus and esophageal adenocarcinoma. *J. Gastroenterol.* **2016**, *51*, 560–570, doi:10.1007/s00535-015-1133-5.

94. Cormie, P.; Zopf, E.M.; Zhang, X.; Schmitz, K.H. The Impact of Exercise on Cancer Mortality, Recurrence, and Treatment-Related Adverse Effects. *Epidemiol. Rev.* **2017**, *39*, 71–92, doi:10.1093/epirev/mxx007.

95. Lugo, D.; Pulido, A.L.; Miños, C.G.; Issa, O.; Cusmir, M.; Horvath, S.A.; Lin, J.; Santana, O. The effects of physical activity on cancer prevention, treatment and prognosis: A review of the literature. *Complement. Ther. Med.* **2019**, *44*, 9–13, doi:10.1016/j.ctim.2019.03.013.

96. Silva, F.C.D.; Iop, R.D.R.; Andrade, A.; Costa, V.P.; Gutierrez Filho, P.J.B.; Silva, R.D. Effects of Physical Exercise on the Expression of MicroRNAs: A Systematic Review. *J. Strength Cond. Res.* **2020**, *34*, 270–280, doi:10.1519/JSC.0000000000003103.

97. Improta Caria, A.C.; Nonaka, C.K.V.; Pereira, C.S.; Soares, M.B.; Macambira, S.G.; Souza, B.S.F. Exercise Training-Induced Changes in MicroRNAs: Beneficial Regulatory Effects in Hypertension, Type 2 Diabetes, and Obesity. *Int. J. Mol. Sci.* **2018**, *19*, 3608, doi:10.3390/ijms19113608.

98. Ultimo, S.; Zauli, G.; Martelli, A.M.; Vitale, M.; McCubrey, J.A.; Capitani, S.; Neri, L.M. Cardiovascular disease-related miRNAs expression: Potential role as biomarkers and effects of training exercise. *Oncotarget* **2018**, *9*, 17238–17254, doi:10.18632/oncotarget.24428.

99. Ultimo, S.; Zauli, G.; Martelli, A.M.; Vitale, M.; McCubrey, J.A.; Capitani, S.; Neri, L.M. Influence of physical exercise on microRNAs in skeletal muscle regeneration, aging and diseases. *Oncotarget* **2018**, *9*, 17220–17237, doi:10.18632/oncotarget.24991.

100. Faraldi, M.; Gomarasca, M.; Perego, S.; Sansoni, V.; Banfi, G.; Lombardi, G. Effect of collection matrix, platelet depletion, and storage conditions on plasma extracellular vesicles and extracellular vesicle-associated miRNAs measurements. *Clin. Chem. Lab. Med.* **2021**, *59*, 893-903, doi:10.1515/cclm-2020-1296.

101. Faraldi, M.; Sansoni, V.; Perego, S.; Gomarasca, M.; Kortas, J.; Ziemann, E.; Banfi, G.; Lombardi, G. Study of the preanalytical variables affecting the measurement of clinically relevant free-circulating microRNAs: Focus on sample matrix, platelet depletion, and storage conditions. *Biochem. Med.* **2020**, *30*, 010703, doi:10.1161/BM.2020.010703.